Polymalic acid-based nanobiopolymer compositions
AssigneeCedars-Sinai Medical Center
InventorsSatoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
Life of this patent
Estimating the term…
Abstract
Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.
Claims55
A drug delivery composition for treating a cancer in a subject comprising:
- a plurality of biologically active molecular modules comprising at least one module that targets a tumorigenic cell or a cancer cell, at least one module that inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein in the tumorigenic cell or the cancer cell, and at least one module for cytoplasmic delivery;
- and
- a polymalic acid-based molecular scaffold, wherein the molecular modules are covalently linked to the scaffold.
A kit for treating a patient having a cancer comprising a drug delivery composition comprising a nanobiopolymeric conjugate of a scaffold comprising a polymalic acid (PMLA) and molecular modules comprising an antisense molecule that substantially inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein, a molecular module to facilitate delivery of the antisense molecule to cytoplasm, at least one targeting antibody specific for the HER protein, at least one antibody specific for a tumor vasculature protein, and a molecular module that prolongs circulation of the composition, wherein the PMLA is covalently linked to the molecular modules, in a container.
A method for treating a cancer in a subject, comprising:
- contacting the subject with a drug delivery composition comprising a polymalic acid (PMLA) covalently linked to a plurality of molecular modules comprising at least one module that targets a tumorigenic cell or a cancer cell, at least one module that inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein in the cell, and at least one module for cytoplasmic delivery, wherein the drug delivery composition is effective for at least one of inhibiting tumor growth, tumor regression and eliminating cancer in a subject.
Dependencies are inferred from the claim text.